PharmaFluidics Raises 2.7 Million Euros for Funding
PharmaFluidics has announced an additional 2.7 million Euros worth of funding to support its commercial launch and expand its analytical applications portfolio to biomarkers, diagnostics, and drug development.
Photo Credit: Vintage Tone/Shutterstock.com
PharmaFluidics has announced an additional 2.7 million Euros worth of funding to support its commercial launch and expand its analytical applications portfolio to biomarkers, diagnostics, and drug development.
Founded as a spin-off from the University of Brussels (VUB) in 2010 with a decade of top-level academic research as its foundation, PharmaFluidics aims to increase efficiency and resolution in liquid chromatography (LC) with ease of use and robustness, opening the way to further miniaturization and integration.
The company confirmed much of the funds will be used to speed up the commercialization of its range of microchipâbased chromatography cartridges. The cartridges are designed for use in biomarker, diagnostics, and
drug research and development applications across biotechnology and pharmaceutical industries. The remaining funds will be used to develop new application fields and reference cases, to broaden the market beyond the current pioneer users.
“These micro-chip columns have an immediate design and performance appeal to pioneer users in the pharmaceutical research and development segment,” said Johan Devenyns, Managing Director of PharmaFluidics. “We believe that ‘secondary features’ such as convenience of use, workflow simplification, column longevity and robustness, and reduced solvent consumption will allow for the future generations of microchip columns and cartridges to gain substantial market share. There is also a bright future for microchip-based columns to be used in combination with simplified, lower cost MS systems, which will become affordable in many more settings and places,” he added
PharmaFluidics also announced a presentation by Johan Devenyns at the “Knowledge for Growth” conference on 18 May 2017 in Ghent, Belgium.
The presentation will discuss micro-chip, pillar array columns, and monolithic chromatography separation beds and present examples of cell tryptic digests and plant tissue extracts to demonstrate the potential of the micro-chip technology. - L.B.
For more information on PharmaFluidics please visit: www.pharmafluidics.com
For more information on the “Knowledge for Growth” conference please visit: www.knowledgeforgrowth.be/en
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
